Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer - PubMed (original) (raw)

Clinical Trial

. 2008 May 1;14(9):2710-6.

doi: 10.1158/1078-0432.CCR-07-4636.

Janice M Walshe, Douglas R Rosing, Neelima Denduluri, Arlene W Berman, Ujala Vatas, Margarita Velarde, Catherine K Chow, Seth M Steinberg, Diana Nguyen, Sherry X Yang, Sandra M Swain

Affiliations

Clinical Trial

Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer

Chia C Portera et al. Clin Cancer Res. 2008.

Erratum in

Abstract

Purpose: To evaluate safety and efficacy of trastuzumab with pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who had progressive disease on trastuzumab-based therapy.

Experimental design: Patients with measurable HER2(+) metastatic breast cancer, < or = 3 trastuzumab-based regimens, and left ventricular ejection fraction (LVEF) > or = 55% received 8 or 6 mg/kg trastuzumab and 840 mg pertuzumab i.v. followed by 6 mg/kg trastuzumab and 420 mg pertuzumab every 3 weeks. Cardiac evaluation and tumor response were assessed every 3 and 6 weeks, respectively.

Results: Eleven patients received 64 cycles of trastuzumab plus pertuzumab. A total of 92 echocardiograms and 8 cardiac magnetic resonance imaging studies were done. With the lower limit of normal LVEF 55%, left ventricular systolic dysfunction was observed in six patients, three grade 1, two grade 2, and one grade 3 according to the National Cancer Institute Common Terminology Criteria for Adverse Events. The objective response rate was 18%. Two patients had partial responses, three had stable disease, and six had progressive disease. The median time to progression was 6 weeks. In baseline tumors from formalin-fixed paraffin-embedded primary and/or metastatic tumor biopsies, pHER2-Y1248 trended toward an increase in patients with partial response compared with those with stable disease/progressive disease (P = 0.095).

Conclusion: Trastuzumab plus pertuzumab may have clinical benefit in selected patients who have previously been treated with trastuzumab. Cardiac toxicity, although asymptomatic in most cases, was associated with this treatment. Further evaluation of efficacy of this combination is required to define the overall risks and benefits.

PubMed Disclaimer

Figures

Figure 1

Figure 1

LVEF in all patients treated with trastuzumab combined with pertuzumab (A); LVEF in patients with LVSD (B) Abbreviations: LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; Pt, patient; C, cycle of treatment; F/U, follow up.

Figure 2

Figure 2

IHC staining indices of HER2 pathway markers and the percentage of Ki67-positive cells of a patient with progressive disease Abbreviations: IHC, immunohistochemistry; T/P, trastuzumab/pertuzumab.

Similar articles

Cited by

References

    1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001(344):783–92. - PubMed
    1. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005(353):1673–84. - PubMed
    1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72. - PubMed
    1. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–48. - PubMed
    1. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–26. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources